Oxford Biodynamics PLC is a global biotechnology company leading the world in the study and commercialisation of Epigenetics, the 3D analysis of the genome. The company is listed on the AIM market and has a market cap of £25m.
Following the publication of the half year results on 30 May, CEO Jon Burrows and Chair Matthew Wakefield, gave an update on corporate performance, the company strategy and the opportunities ahead. A recording of the webinar is available here.
Oxford Biodynamics was founded in 2007 and listed on the AIM market in 2016. The company is the global leader in 3D Genomics and is developing diagnostic blood tests for large addressable healthcare markets. The flagship Checkpoint Inhibitor Response Test (CiRT) was launched in early 2022, has had considerable early sales success and the company plans to launch a Prostate Specific Episwitch (PSE) test for the diagnosis of prostate cancer by the end of 2023. Progress has also been made in the validation of an ALS (Motor Neurone Disease) test in clinical trials.
Oxford Biodynamics success and future potential is based around its leadership position in 3D genomics, where the regulation of genotype and epigenetics intersect, and where they have developed a world leading understanding of the 3D structure of the genome. This knowledge is protected by 18 patent families and is enabling precision blood tests for the detection of life-changing diseases. Industry recognition has come in OBD’s membership of the National Institute of Healthcare (NIH) Biomarker Steering Committee (OBD is the only diagnostic company represented) and from the award of 2 PACT grants to help develop the Episwitch platform as the industry standard for 3D genomics. OBD already has the largest curated 3D genomics database and has worked on 10,000+ samples across 30+ diseases.
Getting to the personalised tests that can be commercialised and sold into the market involves a four step process which has taken 10 years to build and the last 3 years to fine tune. 1) The 3D genome has been mapped and the 1.2m critical regulatory anchor points recorded; 2) A custom chip based on Agilent array technology was built which interrogates the 3D genome and enables it to be profiled; 3) Data is fed into a database to create the world largest 3D genomics database; and 4) diagnostic tests are built that can be applied precisely to different diseases. From blood sampling to…
